BIO
Bio-Rad Laboratories, Inc.Healthcare / Medical DevicesINTACTBio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Price vs. Intrinsic Value Corridor
Overvalued vs DCF ($262.06)Historical market price overlaid against conservative DCF Fair Value & Benjamin Graham Margin of Safety bands.
2-Stage Discounted Cash Flow (DCF) Workbench
Conservative intrinsic value model based on owner cash generation over a 10-year investment horizon. Opens with LocalAlpha's baseline assumptions (matching the fair value shown above) — adjust any input to stress-test.
| Year | Yr 1 | Yr 2 | Yr 3 | Yr 4 | Yr 5 | Yr 6 | Yr 7 | Yr 8 | Yr 9 | Yr 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Projected FCF ($M) | $299 | $316 | $333 | $352 | $372 | $388 | $406 | $424 | $443 | $463 |
| Present Value (PV) | $274 | $266 | $257 | $249 | $242 | $232 | $222 | $213 | $204 | $196 |
Benjamin Graham & Buffett Value Models
Classical deep value metrics based on asset backing, normalized earnings power, and owner cash yield.
Calculated as √(22.5 × EPS × BVPS). The maximum theoretical price a defensive investor should pay based purely on asset book value and current earnings.
Formula: V = (EPS × (8.5 + 2g) × 4.4) / Y where g is the conservative 7-10 yr growth rate and Y is AAA Bond Yield.
True distributable cash flow: Net Income + D&A - Maintenance CapEx. Reflects the cash Buffett would extract without hurting unit volume.
Reverse DCF: Market Growth Expectation
FAIR BARRIERAt the current price of $373.86, the market is assuming the business will compound Free Cash Flow at 10.6% per year for the next decade with a 9% hurdle rate.
Surveil BIO with Mathematical Margin of Safety Rules
Set non-negotiable floor rules for Bio-Rad Laboratories, Inc.. If a newly filed quarterly 10-Q breaks your ROIC floor, operating margin boundary, or balance sheet leverage rules, receive an autonomous breach audit within 15 minutes.
ROIC > 15% • Margin > 15% • D/E < 0.5x
Current Margin 11.2% • Floor > 10%
Altman-Z > 2.6 • Current Ratio > 1.5x
Frequently Asked Questions: Bio-Rad Laboratories, Inc. (BIO) Intrinsic Valuation
Audited fundamentals, DCF intrinsic value sensitivity, and thesis break detection parameters for Bio-Rad Laboratories, Inc..
Related Healthcare Value Stocks & Sector Peers
Compare Bio-Rad Laboratories, Inc. with audited intrinsic valuation models across the Healthcare sector.
Eli Lilly and Company
Drug Manufacturers - General
UnitedHealth Group Incorporated
Healthcare Plans
Johnson & Johnson
Drug Manufacturers - General
AbbVie Inc.
Drug Manufacturers - General
Merck & Co., Inc.
Drug Manufacturers - General
Thermo Fisher Scientific Inc.
Diagnostics & Research